Patrick Johan Hendrik Krol

Part of UnitedHealth Group, Inc., UnitedHealthcare, Inc. is a health care company based in Edina, MN. UnitedHealthcare is dedicated to simplifying the health care experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. The company offers a full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1.5 million physicians and care professionals, and 7,000 hospitals and other care facilities nationwide. Additionally, UnitedHealthcare provides health benefits and delivers care to people through owned and operated health care facilities. The company also offers dual special needs plans that combine the benefits of both Medicare and Medicaid into one simple health plan. UnitedHealthcare is working with state and local health departments and the CDC to provide updates about coronavirus (COVID-19) and information on how to access care, resources, and support. The company was founded by Patrick Johan Hendrik Krol and Brian Thompson has been the CEO of the company since 2021.

Part of Takeda Pharmaceutical Co., Ltd., Shire International Licensing BV is a Dutch biotechnology company. The company is based in Amsterdam, Netherlands.

Aquapharm Biodiscovery Ltd. discovers and develops drugs. It develops products for application across the pharmaceutical, personal care and nutrition sectors. The company offers antibiotics, inflammation & dermatology, oxidative stress, high value ingredients and anti-oxidant ingredients. Aquapharm Biodiscovery was founded by Kathryn Fraser and Andrew Mearns Spragg on April 11, 2000 and is headquartered in Edinburgh, GB.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.

F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The company is based in Cambridge, UK and was founded in 2016.